{
    "9f978634-637c-472f-a588-6f4bb2fb121f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "患有肺炎和肺炎的妇女或不合格接受初级试验或次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3
        ],
        "Secondary_evidence_index": [
            2,
            9
        ]
    },
    "20b34e62-97c2-4ca0-bb1d-7824dab0b8bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "没有精神健康、体重、肿瘤大小、卡诺夫斯基/ECOG分数或预期寿命的条件,需要满足才能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "893a5337-2aa9-4a87-a020-4c2f03cd4aea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "第二项试验要求病人年龄超过一定年龄,但第一项试验没有指定参加年龄范围。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d401affc-f081-4eee-bd61-d109cc88f6de": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "目前参加二级试验的病人不能同时参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "791790a6-187b-4e4b-be5f-9e5304e9ec2c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "HER2+在整个试验期间,初级试验中的病人接受了与第二期试验的2组患者相同的Tastrozumab剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "b95b7438-ec16-4d4d-826d-5891e7982b36": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "在初级试验或次级试验中,没有出现厌食症、低温症或幻觉的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4988cb16-7dbb-4847-84e0-4a7957b32c72": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "在过去一个月内接受器官移植的病人,仍处于卧床状态,将被排除在初级试验之外,但可能符合二级试验资格",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e244fc3a-53b3-4158-99c5-a45afc726af6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "任何对头孢素或三甲普林/硫法甲基沙唑有记录过敏的病人,均不能参加二级试验,而对 levofloxacin 或 celecoxib 有记录过敏的病人也将被排除在初级试验之外。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            24
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "56530063-b408-47f2-8421-6be825f5559c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "初级试验中的介入是通过不同的途径进行的.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d3379655-55b7-4e58-88c2-c3cd3e8cb557": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "经 ER+确认的新诊断IV期乳腺癌的妇女 乳房切除术可接受初级试验和二级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7bf988b4-5e6f-41c4-bef6-7b3549dd58d9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "被組織學證實的第4期乳腺腺癌(英语:Stadium 4 breast adenocarcinoma)是 ER 陽性、PR 陽性或 HER2/neu 陰性,患者可以接受二次試験和初級試験。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4
        ]
    },
    "84915e35-a8c9-4d26-ad09-4b1df48a6df8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "二次试验和初级试验的结果包含完全不同的结果措施。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "64df451c-f868-49e6-9b4e-a325e62ce837": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "初级试验的参与者没有获得任何疫苗",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "dc4765a3-6168-4594-969b-3ce5ea7dc02a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "首次试验的A组和B组均用相同的三剂LDV934的电蒸射注射液",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9c2ca035-d531-4d44-876e-6ed9f2d3f76b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "二级试验和初级试验在其结果中使用不同的测量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "7238ddd4-eade-4b88-8933-0c3df5be9875": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "初步试验组与实验组的结果无显著差异,第二期实验组和实验组均产生相同的结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "主要试验中,6周多服用高-228+塔莫西芬的病人,细胞表达K67的百分比下降了5%",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "204d5293-d6e5-452a-8961-3b76d6be35c9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "初级试验第2组的手术时间比第1组高,因此术后影像学表现比标准影像学表现更好。二级试验中没有与此比较的控制组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "主要试验组1的心脏相关AE记录有几种不同的情况",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9,
            10,
            11
        ]
    },
    "6d0812b9-f9bd-4cd6-82aa-9c272eba23be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "初级试验和次级试验的病人患了血栓栓塞事件.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fd0fa999-2f1c-400d-977d-2d45dd9c358c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "在初级试验中进行介入1,而二级试验中的所有介入药物必须用静脉注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "571d4650-e64b-4cb2-b719-0d7064e51745": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "在初级试验中,肝毒性病例比高血压和胰腺切除病例多十倍",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "4437aa5b-4b4e-4eb4-a258-e7f17dc8f363": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "只有有限的自我照顾能力;被限制在床上或椅子上超过50%的醒来时间可以参加初级试验和二级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "d7abbd7d-a767-49c0-bc99-1c28074eac21": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "初级试验的第1组没有报告任何Aes,但几乎所有第2组的候选人至少有1个Ae",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "54c7e880-a1bf-4206-9573-1c994932ba15": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "在过去的2周中接受化学疗法或放射疗法的病人,患有不稳定的心绞痛,或患有2级或以上神经病的病人,不能参加第二期试验,但仍然可以参加初级试验,除非他们有无治愈的外科创伤。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            14,
            15,
            23,
            24,
            27
        ]
    },
    "f9f0ba74-16e0-4790-afa0-b7616b256e5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "二级考试的考生必须符合某些表现状态条件才能参加考试,而这并不要求被接受初级考试",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "412583db-ce19-451d-a804-3837e4dcaea3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "冠状动脉狭窄是初级试验中最常见的 AE",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "bca4c94d-4a49-4e05-82ed-0d5c9707685b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "初级试验中的介入包括一个药物,而次级试验中,介入需要至少3种不同的药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "97acf304-2707-4a1b-81e7-339fde2ed0ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "患有先天性痴呆症或混合痴呆症的病人可以参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4
        ]
    },
    "21a5f296-5b3c-4860-be64-77ffb8f76501": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "初级试验的两组参与者人数相同",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            13
        ]
    },
    "8d27bb53-e66e-4eab-bea4-0597fd5760b5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "患有肺栓塞史且目前有乳房植入术的病人不能参加次级试验或初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            20
        ],
        "Secondary_evidence_index": [
            12
        ]
    },
    "dc60304d-6fd2-4b12-9108-b5ce78454d42": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "初级试验的总不良反应较二级试验少,但初级试验的心脏缺血/梗死病例较二级试验多",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "328417f9-8f45-4114-82d7-9396b6bc578e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "初级试验的病人需要在8日接受一次注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "40d84c7b-e126-4d6f-9588-eb9c385ca716": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "第2组接受0.5ug/kg的肌痛(5ml),第二组患者不接受任何肌痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b685be77-9c55-4948-99cc-2a249739a233": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "2至3次脑转移的诊断将导致被排除在二次试验中,但有此诊断的患者仍可能在初级试验中获得成功。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            13
        ]
    },
    "5fbee4f6-43fc-45a7-88c4-3dcd5ff21053": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "患上甲状腺癌的病人不适合接受初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ]
    },
    "8127d46a-3a48-4173-8d00-75e949755a74": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "在过去一年内使用加巴芬汀或赫塞丁的治疗将导致被排除在二次试验中,但不会被排除在初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            18
        ],
        "Secondary_evidence_index": [
            12,
            13
        ]
    },
    "576967ff-d2bb-4d1c-b2a1-8516ceb7a519": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "在初级试验中,安慰剂介入和梅曼汀介入都口服一次,每天一次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "fd334e71-2bbe-4138-b578-2ab848686045": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "基于CBT的治疗对初级试验的候选人是禁止的,但他们仍然可以获得第二级试验的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            31
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "a72ddea5-ee4b-4895-bd8c-10b4a143c3f8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0/7的初级试验参与者,和0/1674的次级试验参与者遭受了AE。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "初级试验组2口服安扎卢塔米德,而组1口服IV",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d1118512-9c0b-4480-ab67-d4e0c7de390d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "在过去3年内患肺栓塞的病人不参加初级试验,但根据调查人员的决定,他们可以参加次级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "d35e9b96-20fc-4778-a7db-e87c861c4938": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "两组主要试验中,超过1/3的病人在约7个月后,在乳腺及轴关节淋巴结病理全面反应中经历了",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "25b01c06-612c-4cfb-b30b-50ebe4d98750": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "初级试验第2段的执行时间比第1段高,因此控制组在这方面表现较测试组好。在二级试验中,没有一个可以比较的控制组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1a76bce8-07e2-4b30-adc8-3c095f0d62b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "试用期间,在几个阶段,初级试验的病人接受了与第二期试验的2组患者相同的Tastrozumab剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "23f84ae0-fd01-4799-8872-118e22a015e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "初级试验中只有三种不同类型的不良反应,即胰岛炎、胆石病、肝痛和 Febrile neutropenia",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "c2aea351-6ce5-4d26-9ba5-2632c6367b93": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "在初级试验中,至少有一个病人经历了几个不同的不良反应",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "针灸患者在初级试验中发现,他们的淋巴腺肿比用睾丸激素注射的病人有更好的改变。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "5af6aa8c-69f5-44a5-9c7c-6c94a0fda6e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "在二级试验中,只观察到眼睑浮肿、上消化道出血和胸部疼痛,在初级试验中没有出现",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "455d059c-c3c4-4a09-be0d-a14b9568a0d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "初级试验的第1组接受 PR 负、 ER 负和 HER-,而第2组接受 HER2+",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6d37ed53-a6e4-403e-8b93-9954a6486dbc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "激光辅助荧光血管造影在初级试验中用于两种介入。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "e530eed4-ee8b-4a7f-bb36-5ce9ea7ddebe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "初级试验的2/73人,次级试验的0/1674人患急性心肌梗死",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "41a0138d-7084-40d9-99ae-24db9e84acce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "初级试验是评估治疗相关不良事件患者的数量,而次级试验则以分钟计量其患者的睡眠时间。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "11cb71ed-1304-42f0-b416-3679c3e9e1b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "只有初级试验的第1组将视教育DVD作为介入的一部分,第2组将接受常规剂量放射治疗",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "6ddf4b5b-69e2-46e1-b032-69c3173fd8ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "初级试验采用1个月的周期进行干预,而次级试验则没有循环治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9349c7c8-7771-4dfc-8981-3c8d84ac5236": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "正在考虑人工知能治疗的患者被诊断为Ducktal carcinoma in situ符合初级试验资格。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "4e91cee2-910e-4f08-8a85-1f13545391c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "初级试验的每个参与者都获得相同的干预,无论他们是否患上了癌症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "18c281a1-43bd-47f5-9534-feddfcf0a282": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "初级试验的两组患者在同一频率接受相同的剂量多克塔克勒、多克索鲁比シン和环磷酰胺,但第2组患者包括3个额外的治疗周期",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "dd3d2183-d062-41ed-af63-ae475f2246ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "在一次性试验和二次性试验中,有超过30%的参与者出现几个不良反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "711fdd40-52ec-401c-90fc-5a11de547ab6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "对于初级试验的候选者来说,饮食紊乱并不常见",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7
        ]
    },
    "49b3b463-a496-404a-a3a5-07cd7d4aaa92": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "只有特定国籍的女性患者可以参加初级试验,对参与次级试验不需要这样的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66,
            67
        ]
    },
    "43b9c2c8-0785-4885-901b-91a1f893858f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "主要的試驗介入包括使用TheraSpheres的放射性栓塞,而二次的試驗介入則是基於ibrutinib和Medi4736。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "43989f85-a059-4dc7-a805-16e081706b2f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "初级试验和次级试验中没有记录过不良反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "282a33db-aed6-4daa-bea6-299f424914bb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "在初级和次级试验中,超过15%的病人在研究期间患上了感染",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            11
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "646691ba-ad29-479f-81dc-131d9710c23b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "脑干细胞中2至3个脑转移的诊断将导致被排除在二次试验中,但这种诊断的患者仍可能在初级试验中获得成功。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            1,
            2
        ],
        "Secondary_evidence_index": [
            13
        ]
    },
    "a0c1da21-1e1f-493b-81e9-4ef133c20090": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "次级试验中最常见的不良反应是贫血,影响了5%以上患者,在初级试验中没有发现过敏反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "439b1eca-f583-4a2b-bd8e-0baae97b4c15": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "一些初级试验的病人在研究的10周中没有任何疼痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "e12e5ed1-9a64-4183-9b9d-419e6679ab3d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "任何患有严重或不受控制的心血管损害的病人都不能参加初级试验或次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "73849f1e-31c6-40c5-ab5c-35d0990ceac2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "被诊断为恶性导管癌的病人可以接受二级试验,但不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f53c5344-36d7-459f-9f84-300e19decced": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "在初级试验中接受安慰剂介入的所有患者均有恶性肿瘤。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            10,
            11,
            6,
            7,
            8,
            15
        ]
    },
    "77fd9a89-4d9b-40ab-b4ad-fcf554ca68d2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "任何患有癫痫 、 溶血症候群或贫血的癌症病人都不能接受初级试验和次级试验.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "99433bba-fce5-4b0a-a076-1f699b51472d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "作为介入的一部分,一些初级试验候选者每天服用1000毫克塔拉佐帕里布",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "135763e3-70fd-478d-991c-717d6ed55bb3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "第一组和第二组接受相同的CUDC-101剂量,但第一组被较常用CUDC-101。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6cbfc99b-6531-412f-bd30-b4a803983831": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "初级试验采用3周周期进行介入,而次级试验则没有循环治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6a3053ef-4495-4c18-9da7-68cf5ed254e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "在放射治疗期间,初级试验中的每个病人都接受100至1600毫克芬坦基亚语言喷雾剂",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "217b0362-9dd0-4f10-8ca5-c097688bb738": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "初级试验中感染、不均匀和恶心病例较二级试验多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d88235dd-c37b-4971-9c1f-42b282ff41c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "第四期癌症的病人如果提供知情的同意,可以接受第二期和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "e6bbed17-0fdf-4008-b56e-4d901490ce1a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "初级试验和次级试验都用pCR作为结果测定,初级试验两组组之间结果差异不大,而次级试验,第2组的结果比第1组要好得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "除在初级试验中使用Sunitinib + Docetaxel + Trastuzumab的病人外,所有患者均有治疗急性不良反应,而不到一半的患者则有严重的治疗急性不良反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "8393ad3d-8521-4316-b69e-64910d8af5e7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "二级试验和初级试验报告的结果使用相同的测量单元。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "cca11232-84c4-44e1-89f1-b57b28643dce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "初级试验和次级试验共记录了超过100个组别的不良反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "cb36e435-6dc9-4e7b-939b-9da6ceef2a49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "在初级试验中,安慰剂和Trabectedin的介入均通过3小时静脉注射,每隔两周进行。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7ce21c0f-ad55-4ff7-a180-5e418fe9afc8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "第四期癌症的病人不适合第二期试验,但他们可以接受初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "42c38d71-6a83-4967-ad81-ec38c6b5aafd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "主要试验组2剂量与组1剂量的两倍",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6c5ebc06-00c4-4cf5-8912-93972ed5a49b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "在过去的2周中接受化学疗法或放射疗法的病人,患有不稳定的心绞痛,或患有2级或以上神经病的病人,不能参加二级试验,但如果他们满足所有相关的包含标准,他们仍然可以参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            14,
            15,
            23,
            24,
            27
        ]
    },
    "32cc173a-b271-47c9-997d-df17ce1c7494": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "在初级试验中所记录的单一不良事件类型中,没有涉及超过一个病人",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b742bc02-cd24-4ae7-b8b8-2a57bbd60d14": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "如欲参加初级试验,病人在最近6个月内不能有腹腔脓肿、消化道穿孔、月经腺癌、中风、暂时性缺血性发作、腹腔脓肿或严重的精神疾病的病历",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            11,
            19,
            1
        ]
    },
    "334b5f86-50c5-4711-994d-31ed67dd4282": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "18岁或以上妇女可参加二级试验和初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "04178e95-d808-4a96-ab85-61eb52c17720": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "在初级试验中,共35例使用Sunitinib + Docetaxel + Trastuzumab的病人患上了“治疗紧急”的不良反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "18d3b58f-42ca-4178-adb6-4a5f0c9fafde": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "在初级试验中,没有一个病人在10周内经历过可想象的最严重的疼痛。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "cfa6601b-af52-4eee-883c-89d42b73e02b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "次级试验患者患贫血、肺炎和昏迷症比初级试验患者多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "f58fda4c-f4fd-44a7-8a0f-5d3a16929709": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "一次初级试验中的一个病人在手术后发生一次手术切口重开的情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "e52afcaa-e5d8-4a1f-ae39-8572a64b0aee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "初级试验的AZD0530 175 mg组在第4周的βCTX中发生显著的百分比变化,高于Zoldronic Acid 4 mg组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "96042d49-2f5a-44af-8899-2d5ba24c0f6f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "经数月高剂量化疗治疗后,原发性肿瘤细胞数量减少,原发性肿瘤细胞数量减少不到10%",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "587e611a-9c3b-4557-b3ca-56a7dcc6ce1b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "在初级试验中,只有一组患者每天接受阿莫达菲尼尔P.O.,在次级试验中,所有患者都接受相同的PDR001剂量,但不同的MCS110剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ea3a7d64-b464-4633-a198-794a4a45b201": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "初步试验结果表明,在手术前7天和乳腺癌手术后14天,每天20毫克的塔莫西芬可平均减少肿瘤的Ki67表达量40%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "58165e03-4aa6-4d0c-8256-dbc92ee900c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "CAPECITABINE每天口服给第2组初级试验的第一21天周期的每名病人",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fa7b34e2-75e6-4bc4-a154-99be5bd6b381": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "与初级试验不同,患者必须在下列基因中诊断出一种突变;包括PTEN、BRAF、KRAS、NRAS、PI3KCA、ErbB1、ErbB2、MET、RET、c-KIT、GNAQ或GNA11",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "7b9338a5-d3a8-405f-a197-736caf32c455": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "初级试验的2组患者较二级试验的1组患者记录了更多的腹泻、腹腔灌注和腹部疼痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8f078a17-14cd-4bbc-a9b6-b377ffa077b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "初级试验中至少有1例消化道不良反应及2例以上精神病反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "2d36fa83-b68c-420e-873f-e69374d0741f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "初级试验在介入1中使用Lenalidomide的剂量高于二次试验使用Lapatinib的剂量,初级试验的介入持续较长一段时间。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6e1489a6-3a42-4b52-b690-fb1dd8892749": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "初级试验中所有记录的Aes发生在1组病人身上",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "de6b5ea7-b593-43b7-8fe0-358991878e86": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "初级试验的病人并没有与二级试验的病人发生同样的不良反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fe5928a4-1a0c-4c41-9b85-8d7785a8ab4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "在初级试验中,只有一组患者每天接受阿莫达芬ilP.O.,在二次试验中,所有患者都接受相同的100 mg的PDR001和1 mg/kg的MCS110。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "827af363-cfd3-4233-9029-e8c7e053c661": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "次级试验中观察到的不良反应比初级试验多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3c9a4b79-1f51-477a-a5b6-b69f76aeedf8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "二级和初级试验采用相同的结果测定;乳腺内pCR患者比例,术后乳腺内无残留侵袭性肿瘤的证据",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "98b04dac-b155-4afd-8855-03ed818df5d9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "我们不能比较初级试验和次级试验的不良反应,因为它们似乎没有在初级试验中记录。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7eeeed55-fe37-47ae-be62-e50557ccaed1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "无论是二次试验还是初级试验都无法测定肿瘤K67表达的变化.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "cbc96b9d-b39c-4fbe-b8a7-e7df7490881b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "有13 % 的 PR+ 初级乳腺癌患者接受 HER2 靶向 PET/CT 治疗 89Zr-trastuzumab 发展 HER2+ 转移",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "2a05996c-d5fb-4aa8-9654-fb1d27180888": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "初级试验第2组的患者患中性白血病的次级试验第1组的患者患中性白血病的次级试验第1组的患者患中性白血病的次级试验第1组的患者患中性白血病的次级试验第1组的患者患中性白血病的次级试验第2组的患者患中性白血病的次级试验第1组的患者患中性白血病的次级试验第2组的患者患中性白血病的次级试验第1组的患者患中性白血病的次级试验第2组的患者患中性白血病的次级试验第1组的患者患中性白血病的次级试验第2组的患者患中性白血病的次级试验第1组的患者患中性白血病的次",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "da24d6fd-1363-489b-ac5a-f44dbe622c5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "低钙症患者被排除在初级试验之外,但高钙症患者可能有资格参加二级试验和初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "437d5311-f0fd-4d61-82a2-5db0d07415f6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "初级试验的介入是口服的,而次级试验的介入是通过插入静脉的针或管进行的",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "非裔美国患者可以参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "2bd78232-4872-4d66-ade9-836190b86e1d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "有肿瘤性脑膜炎的病人可以参加初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ]
    },
    "80a26581-a95c-4c22-864f-93425b1fc165": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "初级试验第一组的大多数患者在介入后进行筛查时都保持最新状态,无论癌症的类型如何。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "4c926c31-8786-47b0-a032-1d59f759bca5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "初级试验和二级试验进行口头干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "62384871-8eb2-414b-8cc9-e756a188e19e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "不同介入的初级试验和次级试验报告,次级试验病人的MTD为每日15毫克",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a6e81477-f863-4a83-9007-fd2f1f5c6781": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "乳腺癌和卵巢/腹膜癌患者在初级试验中接受同样的介入。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2312576f-7c8d-4fcd-80e8-42cf3d81dd04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "初级试验1组患者接受的Eribulin剂量高于2组患者接受的Docetaxel",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8f4d4e78-5e46-47b6-865c-ad6b689d69e0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "在第二期试验中,被记录的患胸疼痛的病人远多于初级试验的病人。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "a8268e5e-d758-4dcf-8dd9-78c2016bc7f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "两组初级试验组均接受术前德克萨米沙酮",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d53cf5fe-1104-4b05-886c-bb5499cdc047": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "所有在初级试验中记录的不良事件都与肌肉骨骼系统有关,但二级试验并非如此。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1bd849aa-409c-4214-a930-4d187a645466": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "第一组和第二组接受相同剂量、相同频率的CUDC-101,唯一的区别是第一组也每周一次接受PD-0332991。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a5415a49-0b04-4f8f-a7ec-a8c276b2cf64": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "次审的胆固醇和腹泻病例比初审多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            2,
            5
        ]
    },
    "5578e4a3-95d9-4803-8d13-b9c0276f92e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "初级试验的两组患者在同一频率接受相同的Docetaxel、Doxorubicin和Cyclophosphamide剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5e92a3fd-5ffa-49db-9978-897321839068": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "初级试验的第1组和第2组采用相同的呼吸指令CD,但第2组每隔两次练习,每周接受抗neoplastic化学治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "539bf07d-199d-4c9b-af16-5f314962bcfc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "即使患者满足了初级试验的所有排斥和包含标准,最终的包含决定将由亲属患者作出。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "00831e0c-eaad-4fe9-a791-f105815fa215": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "严重失眠的病人不参加初级试验和次级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            6
        ]
    },
    "0a266c52-2a4e-4aed-a04c-85c148f2cd41": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "初级试验的Bevacizumab组比Bevacizumab+Capcitabine组获得更好的结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "4e5a04a1-2513-472b-b2a7-891d68a3b549": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "初级试验的 ER 阳性光线B组的参与者比 Triple Negative组的参与者显示增长因子签名下降了11%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "6734e552-d882-446e-a02f-c6bbe2eeb6ed": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "一個32歲的病人,其乳腺癌III期的病態已經經組織檢查,血清濃度為1807/≈í¬∫L,血小板濃度為110,034/≈í¬∫L,血清濃度為90 g/l,平均壽命超過8個月,可以接受初級和次級試驗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            10,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3,
            4,
            7,
            8,
            9
        ]
    },
    "3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "第1组或第2组的初级试验中,没有1名患者显示出40个被评估基因表达的可辨模式",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3a4198ab-ae79-4200-b073-860b2e86813d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "患有肺栓塞史的病人不能参加次级试验,而目前有乳房植入者则不能参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            20
        ],
        "Secondary_evidence_index": [
            12
        ]
    },
    "327d67d2-35e7-45c3-958a-7955905f2d57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "在过去两个月中患肺栓塞的病人不参加初级试验,但根据调查人员的决定,他们可以参加次级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "a1807b6a-6ee6-4c74-bf44-53d39c31c66f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "次级试验对所有参与者均适用相同的包含/排斥标准,而初级试验则有两套包含标准,一个是18至50岁年龄组,另一个是50岁以上年龄组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "df39cd99-7291-4749-a7d5-ff760b7c3fc2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "次级试验的2组比初级试验的2组获得更好的结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17,
            18,
            19,
            20
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            7,
            16
        ]
    },
    "54a1eab3-1e8e-4c1c-a30f-f4d677a84c71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "初步试验的结果表明,A组干预反应比安慰剂组反应要好,此外,在第二期试验中,Denosumab组比Zoledronic Acid组的SRE时间较早。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cc6601cf-3aa0-44f7-8476-f3dfc34e7412": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "初级试验是用 topical干预,二级试验是用吸入干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7d60c7dd-fb79-4e95-a662-32de2036683f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "主要试验中,共有两名患者在两组中患上了限制剂量毒性的发病率。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "c12d4dba-17b9-45d6-9a3f-75be190b7795": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "初级试验和次级试验在他们的群体中记录了同样数量的不良反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8aca5f0b-c998-4e51-9e53-e23294e61867": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "初级试验中的介入1用IV注射,二级试验中的所有介入药物可口服。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "88857141-6207-4828-b8d4-09d7cc4498c3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "在上个月内接受器官移植的病人,将被排除在初级试验之外,但可能符合二级试验资格",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "Sunitinib每天被口服给所有初级试验的病人,整个研究期间。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "急性呼吸干预组的初级试验病人平均患病率高于急性呼吸干预组的快速、浅呼吸组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f03664fa-20b3-4102-b1e2-fe901d028f65": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "年龄在18岁或19岁的妇女可以参加二级试验,但必须等待1-2年才能参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "95cb9c0a-0725-4108-aebb-f114f77b577c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "接受过高剂量化学疗法治疗后,原发性肿瘤细胞数量减少,原发性肿瘤细胞数量减少",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "726add6d-9f17-4e3e-a43e-8b391fbb953b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "初级试验的患者在整个研究期间都将获得高剂量α Lipoic Acid,而第二期试验的第1组患者则在整个研究期间都将获得相同的剂量Nekitumumab。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8c07a493-66a5-4728-ae22-d6c45b2215a8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "初级试验1组和2组的差异是,1组每天给予25至37.5 mg的苏尼尼尼比,而2组则接受10 mg/kg的贝瓦西苏马布",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9340e38d-37ce-4634-9f36-a747f964441c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "所有初级试验的候选者必须有由IHC3+证实的HER2阳性肿瘤,同时需要大量协助和频繁的医疗",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "b20cbb69-8909-4a66-b47c-27192604d187": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "初步试验的结果表明,武器A的介入提供了最佳的整体反应率,此外,在二次试验中,丹索马布群组比佐利德隆酸群组有较差的初试SRE时间。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b5f68d8f-0c92-4f58-9740-78556c039e58": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "NUT中线癌(英语:NUT midline carcinoma)或抗卡斯特雷前列腺癌(英语:Castrate-resistant prostate cancer),由荧光体位杂交(英语:In situ hybridization)或炎性乳腺癌(英语:Inflammmatory breast cancer)的患者可以接受初级试验和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d475c476-8172-47a0-bf91-7ef5d0f6d081": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "初级试验的参与者接受全乳腺放射治疗,而二级试验的两个组别都接受500毫克富尔维斯特朗,用药片的形式接受BID。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "7f6d7fd9-8aed-472d-af54-b288d16c2135": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "二级和初级试验中,有几个病人患上肿瘤溶血症候群",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "49c63fc5-be4b-4474-8bfc-0ddf9cf438db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "在初级试验中出现的 Bronchopneumonia 和 一般性 身体 健康 恶化 的 病例 比 在 次级试验 中 更多 。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "5887ed1d-aa43-4a18-be3a-9141b675d5af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "第一组的参与者中没有一个人被发现有病变,第二组的95%以上的颗粒有放射性皮肤炎和高色素化。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "fa6115aa-a765-4d03-9fd0-61c97d5e282f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "所有初级试验的参与者,特别是卵巢功能抑制组的认知功能恶化",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "5a916856-536f-444d-87e7-1b2c032c0656": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "至少在一次初级试验中,一个用GTx-0241mg治疗的病人获得超过10公斤的瘦身。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "在初级试验中接受安慰剂介入的患者患上恶性肿瘤的可能性比接受阿普里平特的患者高两倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "ceb02a85-73a3-4c00-823e-fb88bc91d239": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "吸烟者不参加初级试验,但如果他们每天饮用少于5杯酒精饮料,则可以参加二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "3cae8899-5172-460e-8ff1-e6e1c8a59f0b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "二级试验用疼痛作为物理治疗效果的指标,而初级试验研究硫磺酸补充剂对尿中异氰酸盐浓度的影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8367e2fc-f384-43c0-af4e-d4ec41281b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "初级试验1组的大多数患者都曾经历过不良反应,而2组则发生相反的情况。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "20493bc1-bda8-4255-a1d4-40cb499bd845": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "在初级试验和二次试验中,至少有1例感染",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "93eef0e8-7a40-452a-a61e-a9d671dcacbd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "初级试验和次级试验的病人组别中没有肠道阻塞或胰岛素病发症的发生",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3d9a7121-da16-4e7b-a02d-1932f46cbb77": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "次级试验患者患贫血、肺炎和昏迷症比初级试验患者多,但初级试验中记录的 FEBRILE INFECTION病例较多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e2979c27-0eb6-487d-a940-646685e1934b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "初级试验中干预1和干预2的区别是,干预1使用pIHGC,干预2使用stantdard GP。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5abfa152-2c23-40b4-ba00-b28336b8b8b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "即使患者满足了初级试验的所有排斥和包含标准,最终的包含决定将由进行试验的医疗专业人员作出。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "251e979f-a7ba-4dea-afb7-01b9501ec7cf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "基托罗拉克30 mg组的96名参与者在初级试验中经历了无复发生存,而NaCl组的67名参与者则只有0.9%的3ml生存",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "7eab2fc5-fd40-40bc-a960-90aafe45ef9e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "32 岁 的 乳腺癌 第三期 经 组织 核查 的 病人, 绝对 中性 细胞 数 为 1807 / ≈í¬∫L, 血小板 数 为 79000 / ≈í¬∫L, 血红蛋白 水平 为 90 g / l, 预期 寿命 超过 8 个 月, 可以 接受 初级 和 次级 试验 。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            10,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3,
            4,
            7,
            8,
            9
        ]
    },
    "a6299338-84c5-469d-9bd0-eff13b90a7eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "初级试验管理员将其干预语文化,次级试验管理员将其口语化。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5e5253e5-fd72-4f2b-84ba-b370545cd182": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "主要试验组1中记录了几种贫血和 Febrile neutropenia 的病例,但 Pancytopenia 的病例只有0例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "5e301f1c-087e-4ca4-b679-cc229d1c0d27": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "初级试验的介入1和2的唯一区别是,1组与2组相比,其每月注射量减少0.7mg。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0967b501-90dd-4ba4-bebc-8db1e9695431": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "阿尔茨海默病患者不适合接受初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ]
    },
    "8101ccf6-e6f4-43ba-b22f-9a13e2ddd279": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "初级试验的帕克利塔克勒+贝瓦西祖马布+杰姆西达宾组比帕克利塔克勒+贝瓦西祖马布组有更好的ORR,参与者较多",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "292d0dd3-1b9c-4291-b367-0cc1666178db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "初级试验要求病人每月注射120毫克丁诺沙马布,次级试验不需要注射,而是用磷酸盐法注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "ef1d6dfa-2cd0-4e19-99b7-a813d6952706": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "二次试验和初级试验之间唯一共享的包含/排斥标准是提供书面知情同意的能力。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "86ed4db6-24fe-4a88-ba9b-6be3f98e0525": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "LBH589与初级试验的开普西达宾组相比,结果较LBH589和拉帕提尼布组差",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "d71c6377-89da-457d-acbc-827be4ddb8e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "在初级试验中,有一个精神病不良事件,影响了不到10%的病人",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "74aebfd6-c201-4c6f-a7af-7e4e0de6b661": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "次级试验中最常见的不良反应是贫血,在初级试验中没有发现过敏反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "886a066c-520e-4454-bf20-43ad24b6baf9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "在第二期试验中,被记录的患上Aes的病人远多于初级试验的病人。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "2a95f6b8-fbdd-47e6-949f-8aee18a2c605": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "任何日本公民都可以参加第一审或第二审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66,
            67
        ]
    },
    "15d7d028-69c2-4e01-b85c-cff568f34cc1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "厌氧病人可以参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "fdadf425-1eaf-4e63-b034-29afcbe48baf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "在初级试验中唯一被记录的AE是Stomatitis.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "3ad9820f-4ef2-4624-b08a-b910adf25836": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "在初级试验中,阿斯提斯更常见,二级试验中,肺炎更常见。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "afdafe17-63a8-4fca-b923-a2bb964493d1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "过去3年内诊断有扩散性肺病的成年人将被排除在初级试验之外",
        "Label": "Entailment",
        "Primary_evidence_index": [
            19,
            22
        ]
    },
    "a0428861-8e0f-42ca-889f-b2546ae3dbe6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "一个在公元前IV阶段接受乳房切除术的妇女仍然可以参加二级试验或初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e6e3ecde-9d81-41a2-849e-de26c1b9bafc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "初级考试和二级考试的考生必须符合基本成绩,每个考试都采用不同的成绩评分系统。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "f8a72a9e-357d-4786-8d5d-66ee4ce4d1b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "初级试用者需接受7种不同的药物并接受手术,而次级试用者只接受2种不同的药物并不需要接受任何手术",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "81521795-13b4-46d4-a03e-51ab823e9756": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "初级试验中的两种介入包括",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b29091a1-befa-4edc-9bc9-06263826bfdd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "乳腺切除术被确认为 ER+ 的本地晚期乳腺癌新诊断的妇女在初级试验和次级试验中符合资格",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "593bde37-5962-441b-ac10-dbe3120cec99": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "初级试验中,不到5%的病人患上了爱滋病",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d85fd7f3-2765-407e-a8a3-49c19d9a4311": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "患胸膜癌的病人在初级试验和次级试验中可能符合所有研究组的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "b6902408-8d60-438b-bb38-416d4a4d76fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "没有一个主要的审判候选人必须在干预过程中经常锻炼身体",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c484c0e8-0530-47cb-89dc-da4c4a7f4c0b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "初级试验测试不同放射治疗对研究组的影响,而次级试验测试不同剂量相同的治疗对研究组的影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7270c176-7bf2-4b0d-941d-912f5a3ed62c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "在初级试验中观察到0个不良反应,二级试验中没有一个不良反应影响超过30%的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8be0e7b4-f74d-4205-a543-1247762bb467": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "二次试验的介入时间比初级试验的介入时间要长15周。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2c4acb3d-7009-4a19-ac0e-703a96740738": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "只有初级试验的第一组将视《教育DVD》作为介入的一部分",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "401f0d8c-4f4e-4693-8baa-3ae8664480d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "乳腺组织学或细胞学证实的转移及/或高度固体肿瘤的病人,可接受初级试验第一期及第二期所有组别",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "67f1754a-420c-4605-a41d-784c4d1e77b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "在初级和次级两组患者中,共有3例出现血栓。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9727b232-81fc-42cc-bd06-05cc81a7453b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "若患者有一次性肿瘤,半径为3毫米,经临床检查和扫描仪测定,可接受一次性试验和二次性试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "1cdbbd44-21df-4279-9e3c-ff501f1361ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "关于不同干预措施 MTD 的初步试验和二次试验报告",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "78aec7ae-20b1-413b-9cb7-9757274ff1aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "病态肥胖的病人可以参加初级试验.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "b3b66b49-6a4c-4c26-b46c-915ab45374ff": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "初级试验患者接受的放射治疗剂量比次级试验参与者高",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "73876da9-0c79-43eb-9d1f-b7f2d729f43c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "初级试验有1个测试组和1个安慰剂组,次级试验有2个测试组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9c7521a7-87fc-4dc0-8c1e-5720836763e2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "参与者必须对AI疗法和米尔塔扎平有耐药性才能参加初级试验,但这并不必要包括在二级试验中",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ffacecd7-caae-434a-866d-a3a25d4f00ac": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "初级试验的安慰剂介入和合并MSC介入均用跨心肌注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "458419cf-ea6f-4939-ba2e-856b8d89b985": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "二级试验对所有参与者都有同样的包含/排斥标准,而初级试验对不同研究组有两套包含标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "7482499c-6836-4f68-83f4-4af09b14d566": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "初级试验第2组没有死亡或住院",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a0d99371-52e5-4d30-81d5-ad65feba2e4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "两个乳房的可测肿瘤患者不参加初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1
        ]
    },
    "47bcd1c5-f95d-4e21-a999-4bd220c5b940": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "在放射治疗期间,初级试验中的每个病人都必须每天吞下一种沃里诺斯塔特胶囊",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "cc411bc6-900e-4ef3-96ef-09f6e5565a18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "儿童没有资格参加初级试验,但他们没有被明确排除在二级试验之外",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "1943100e-196d-4022-a38a-9ae0dd816294": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "初级试验的干预1和2的区别在于,干预1使用较干预2的放射性Tc99M硫胶体高剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d11356c5-cf48-40dc-aa23-46e71f564afd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "在初级试验中记录的总不良反应和不良反应类型较次级试验少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "f8e8c733-3fc0-4699-814f-b5d505c71435": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "初级试验1组和2组的差异是,1组每天注射25 mg苏尼尼尼比,2组则接受90 mg/m^2帕克利塔克勒",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "dfea11ab-1a3f-4a76-9fae-96d486f76e10": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "希望参加初级试验的病人,在最近6个月内不能有腹腔炎、消化道穿孔、心肌梗死、中风、暂时性缺血性发作、腹腔脓肿或严重的精神病变的病史",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            11,
            19
        ]
    },
    "285b3905-8e47-4b26-8aa5-2d9d7f717a6c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "第二期研究组的候选者每周接受皮下注射(SC),而初级研究组的参与者则不接受任何注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "92935ccc-f20d-4e27-9a5f-cb8d47162de6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "候选者在参加初级试验前必须接受乳房检查,但二级试验并不需要如此。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "74308ad0-4b9d-4632-9580-5e280dedbc77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "任何性别的病人都可以获得初级试验的两个阶段的资格,如果他们有证据显示急诊不良的乳腺癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8,
            9,
            10,
            11,
            12,
            14,
            15
        ]
    },
    "487dd970-35e7-4a7d-8bb6-e8fa98f574aa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "患有骨质疏松症和骨质疏松症的妇女或不合格接受初级试验或次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3
        ],
        "Secondary_evidence_index": [
            2,
            9
        ]
    },
    "1cda1a1d-3ca1-4838-9054-bcab763bb5d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "初级试验第1组所记录的Aes都与心理健康有关",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9,
            10,
            11
        ]
    },
    "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "经组织学/细胞学证实的可逆性非小细胞肺癌或小细胞肺癌的病人,可接受初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32
        ]
    },
    "aecd2958-c3b4-4d87-82f1-07add215b1e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "第一组接受术前德克萨米沙酮,第二组接受术后2小时的德克萨米沙酮。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "590f240e-7499-432e-aa3c-f54eda69ed46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "有生育能力的妇女和性活动、有生育能力的男性可以参加初级试验,但他们必须在整个研究期间坚持戒烟",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            20,
            21,
            22,
            23
        ]
    },
    "561d1a70-6bd1-42f7-9e2a-73b9622a449c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "初级试验有1个测试组和1个安慰剂组,次级试验有1个测试组和1个控制组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1af4d0ac-d0f2-402a-8bdb-0e10c0823b0f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "在一次性试验和二次性试验的患者群中,最常见的不良反应是Syncope,在25.00%的一次性试验患者中发生。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c8235719-3fd8-43e9-8ba6-d99393220240": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "没有精神健康、体重、年龄、卡诺夫斯基/ECOG分数或以前的治疗条件需要满足才能获得初级试验资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "837329c4-d046-4997-ad41-f230d3db7255": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "在初级试验和次级试验中,没有记录心脏或精神病性Aes。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e1040054-0fe6-4c92-be82-f2b5b79282a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "苏拉明和帕克利塔克塞尔在初级试验中被投给所有病人,而次级试验干预部分并没有描述哪些药物应该被投给。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "282c18a2-64b1-47cf-8563-db8db40dadb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "第一组和第二组患者接受相同的放射治疗,并接受SPECT扫描。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "f4e0551c-44e9-44f1-9a50-c65075a51715": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "初级试验的参与者对肝功能没有条件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "cbba3546-5b88-42d0-882d-024d5f267d97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "在初级试验中,术后腹腔炎、腹膜灌注和腹部疼痛的记录较次级试验多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "ea1d804d-bac9-4ebd-a6bd-0705c988927f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "初级试验干预部分没有概述治疗周期或任何治疗的描述",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fdd9ccc8-95c0-48d9-bc4d-3ef7469dbb9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "没有意外死亡或住院,在初级试验或次级试验中发生,唯一被记录的AE是3例淋巴瘤。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "17413685-69fd-453f-af49-29982a6c95b6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "初级试验第1组的参与者用肺结核疫苗注射,第2组的参与者用流感疫苗注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "10292ba1-dd1f-4191-b534-331f39583181": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "低钙症患者不参加初级试验,但可参加次级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "e78805f7-1b81-4cd9-a3c7-591886fd5d70": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "帕克利塔克塞尔只在初级试验中的第1组干预中使用,而第2组则用药剂",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "42857f32-4798-4767-a0c7-f74cdcab7a9b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "初级试验的参与者在整个研究期间接受4种不同的药物,最大剂量为100 mg/m^2",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9c2adaba-1ac9-4a7c-a710-14ac7d2056fd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "初级试验的两个组别都没有在介入中得到任何咨询、风险评估或CBT。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "af55082d-0ff1-419f-861f-80dbd05a9ade": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "初级试验在其2个阶段使用单独的包含和排斥标准,而次级试验在健康和癌症患者使用单独的标准。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "3a0c092c-7e18-4108-ae66-552f7069831f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "在一次性试验和二次性试验中,超过10人死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3a452f00-375b-48c4-96dd-48986c0c0064": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "乳腺肿瘤直径0.2-0.8厘米,经证实有HR阳性及her2阳性,可接受初级试验及二级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ]
    },
    "c94158fd-10f5-4142-a361-5b346ff2c295": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "在二级试验中,胆囊性胆固醇和克罗斯特里dium硬性胆炎的病例比初级试验多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "577c7755-64ae-4b78-bbe3-627cef6e3ece": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "术后约7个月后,两个组别的42名以上患者在乳腺和腋下淋巴结病理全面反应中经历了",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "5b94480e-aa25-491e-ae37-a2b2939eafaf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "所有符合二级试验资格的病人也符合初级试验资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "494a4094-5a05-4c7d-b7a7-60baeb210e5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "在初级试验或次级试验中没有意外死亡或住院",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5b13bca4-0354-4579-a868-d007bef0dbe1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "初级试验中尼拉提尼布组的iDFS率比安慰剂组低",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "623db2b4-6824-42e4-9ad6-39cf3bf14dab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "初级试验的第1组和第2组采用相同的呼吸指令CD,但第2组每天练习两次。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a793df3f-fa04-4d48-a2c6-006589d52e84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "初级试验中,平均两组患者的认知功能恶化,但并非所有患者的情况",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "75961bc5-20b9-4161-83e0-a59429ce18e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "初步试验第一组超过50%的病人在用阿普里平特、德克萨米沙酮、赛托克森和基特里尔治疗后急性呕吐",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d94a09b9-8201-43f3-9b27-cab0bc473af0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "二次试验的介入时间比初级试验的介入时间长3倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6920329b-7559-415e-9346-c06909526421": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "初步试验和二次试验中,没有发生 Febrile neutropenia或Cholelithiasis的病例",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "85d61aaf-5255-4203-9ccf-f9c3da7a352e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "无法测定转移的病人,或癌症未扩散到身体其他部位的病人,不适合接受初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "初级试验中只有2例病人没有无复发的生存",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "0c73bdd4-7244-433c-8b5e-bf335f21701c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "初级试验中出现了一些精神病性不良事件,包括饮食紊乱和精神分裂症",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "b9b156ee-526a-49ac-aa99-78f02a24dbaf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "用荧光体位杂交法测定NUT中线癌或炎性乳腺癌的病人可以接受初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3974c3ec-d3b5-4313-ae4b-4332ee5865ab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "初级和次级考试的考生必须符合基准成绩,初级考试的基准成绩为卡诺夫斯基得分>70,次级考试的基准成绩为卡诺夫斯基得分>55",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "b358fb9c-1152-4e1a-88eb-743e965d58fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "患有重度厌恶性反应的病人不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            17
        ]
    },
    "06b8d395-0fe7-4206-b118-5e478779cce0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "在初级试验或次级试验中,没有患者患过3种不同AE。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "a911fcee-0621-4f06-a511-b8323ab8440c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "无论是二次试验还是初级试验,都未使用治疗急性Aes的参与者人数作为其研究结果的测量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "68f673a5-6ddf-487a-ad88-4903d92e1746": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "在初级试验中没有记录Aes的病人,而第二期试验中的每个病人至少经历了一个不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "93bb8a0e-e84c-4730-b559-22d912103993": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "初级试验在介入1中使用Lenalidomide剂量高于二次试验使用Lapatinib剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0d7d2408-c51f-4b3a-a47f-6f0ee8dedacc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "初级研究报告了两个组别的全部156名患者几个月的进展时间,而次级研究报告了经历目标反应的患者人数",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "102bbdcd-14ea-4dd5-a0bb-4cea343bb6ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "初级试验中记录的口腔黏膜炎、膀胱炎和血栓栓塞病例较二级试验多",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "559c1faa-17b6-42c7-9f63-0cd58df39bfa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "初级试验没有测试任何基于药物的治疗,而次级试验测试两种不同的药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fa586070-5821-4a70-9812-9d7c6e5df330": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "初级试验中5例病人有3次或以上不良反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "所有初级试验的病人每3周至少服用20毫克的MCS110,其他每星期服用130毫克的PDR001。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "有恶性导管癌并无控制高血压的病人可接受二级试验,但不参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            12
        ]
    },
    "851e1a1b-0b8e-4aef-a7e3-f06c036fe537": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "首次试验的1组被给予0.035 mg的ALT-801少于2组",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "初级试验的两个组别都没有在介入中获得任何药物、放射治疗或CBT。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "9e3cf2a2-6713-4d07-adde-e334b49ca6ec": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "初级试用者每星期接受的MM-121和帕克利塔克塞尔剂量比第1组的次级试用者少",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4493c1ed-668a-44d4-9b3e-767f597d4fa8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "初步试验和二次试验中,共有3例哮喘病例和5例白热病例记录在案",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b9074beb-a639-46ba-966b-b0db266efffc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "初级试验干预部分剂量不描述投与方法、剂量或周期。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "017ff04d-5509-4f54-863c-10201351e15d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "在初级试验中,有几个正常维他命D水平的病人显示出40个被评估基因的表达模式。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "cd250e97-c2b4-48cd-bcbe-55ea06fa9662": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "有乳房切除术的妇女仍可接受二级试验或初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "a1a3cda8-7324-4270-aaf9-51ad1b40be07": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "次级试验记录了11个Aes比初级试验多",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "25551d37-108d-497a-8e75-825d8d707190": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "可测量的双侧乳腺癌患者可接受初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1
        ]
    },
    "bc7b62ad-797e-419e-b5f9-888117aedf6b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "在第一审和第二审的Aes中记录了几宗肿胀、低温和混乱的案例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5261c924-d9ef-43ed-8f2a-6c5b1552cc62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "有生育能力的妇女和性活跃的生育男性可以参加初级试验,但他们必须满足一些额外的要求。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            20,
            21,
            22,
            23
        ]
    },
    "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "初级试验参加者的预期寿命、怀孕或年龄无条件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2bf9e0d9-1195-4c03-b2bc-d491ff1cd174": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "36.36 % 的 初级 试验 病人 患 了 血胆碱 的 增加 。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1bf99d45-84a7-41cb-8263-d1ccb489bc66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "在第二期试验中,只观察到眼睑肿和胸部疼痛,在初级试验中没有出现",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "adfed785-8da6-4bf4-836f-2dfadf0510b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "初级试验在其2个阶段采用单独的包含和排斥标准,而次级试验则在所有参与者使用相同的标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "初级试验达洛图苏马布20 mg/kg组的参与者比三重负组显示生长因子签名下降49.2%",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2a0b1a83-299d-404d-96e5-67ee65173dde": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "初级受试者接受全乳腺放射治疗,二级受试者同时接受肌肉注射和口服药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "25cbaa44-4715-417b-9bd0-12fef06053b8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "在初级试验中,不到10名病人患上了麻痹症",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0f31bc6a-a228-49c2-afff-4177ef850272": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "初级试验的参与者比次级试验多",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "bf3034ec-679a-42d1-9d24-69b51c602233": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "性别不是第一审或第二审合格的决定因素",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "fbde81ad-0d06-4d2a-8baa-eb5eace1b3ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "初级试验和次级试验没有对其参与者造成任何不良反应的记录。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5e6797ef-370c-4b35-9e1d-37e694b538a6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "初级试验中25%的病人患上膀胱扩散和急性病变",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "帕克利塔克塞尔在任何一次初级试验中都未使用",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "59a0bff2-c254-45f1-a6ae-2d847777db94": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "初级研究报告了两组共有156名患者的进程时间,而次级研究报告了有目标反应的患者的百分比",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "44412911-1f34-4841-a795-86eed5a209d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "初级试验中所有感染和发烧病例均为1组患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "505ccc8c-b07a-4902-b8c3-4d3b4891779a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "初级试验的病人需要接受几个注射",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "58614e8d-770e-4bfe-b74b-e2d429ef072f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Perjeta在二级试验的两组中都使用,但在初级试验中完全没有使用",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d118efb5-ea31-49ca-8e20-686c85081e94": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "初级试验参与者患上胆石病的频率是次级试验参与者的两倍",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "5a181517-dbdc-4598-8955-ca1bfa380fa9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "初级试验中的介入包括单一药物ZD1839,而次级试验中需要至少3种不同的药物,包括Zoldronic酸、Samarium-153和Pegfilgrastim。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4adbcbcc-ae43-46af-a072-815d1e788f29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "被诊断为CCND1增强、CDK4/6突变、CCND2增强阳性肿瘤的病人不参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "在初级试验中,安慰剂介入和梅曼汀介入均以相同的频率并持续相同的时间进行。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "bd5d8368-5c1d-41b8-9fb3-f174da18744f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "所有在初级试验中用GTx-0241mg治疗的病人在4个月期间获得瘦身质量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "d1a7cbaa-161a-4675-b8b7-67ae364be364": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "无论是二级试验还是初级试验,都用MYMOP分数作为研究结果的测量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "574106ef-1b9c-4540-a89f-5100a9bbe798": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "非裔美国患者可以参加初级试验,但他们必须在研究期间居住在德克萨斯州。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "21c021d2-764d-4028-b945-2aeb525b9888": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "初级试验和次级试验都用pCR作为结果测定,初级试验两组组之间结果差异不大,而次级试验中,第2组的结果比第1组要差,因为第2组患者的pCR比例较高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "aefb2cc5-3101-416b-bae4-c9a1e7d8f39e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "复发性恶性肿瘤、移植与宿主病、感染、精神病变及分发性肺出血在初级试验的不良反应中均较次级试验更为常见。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "320ec115-31c3-47bf-a819-93d514b91eb3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "第一组的参与者没有发现有病变,第二组的90%以上颗粒有放射性皮肤炎和高色泽。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "f45b251f-2fec-44b7-8fc0-dd0d06a44d3b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "在一次性试验和二次性试验中,在超过1%的参与者中没有发生任何不良反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d54a3e9d-5602-4cc3-934e-717f1da39792": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "初级试验结果报告了疼痛强度的变化,次级试验测定了腰椎骨矿物密度(BMD)从基线变化到9个月的变化",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "ce8a4f39-efff-4fd3-b850-4fc5c30270ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "初级试验和次级试验在他们的介入中并没有使用相同的药物、剂量或投药频率,但他们都使用静脉注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9d94e597-591d-409e-a8e2-b205a83533a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "在初级试验中,肝毒性病例比高血压和胰腺切除病例多3倍",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "7e271bbd-26e8-422e-be5c-54d294da815a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "被诊断为雌激素和/或孕酮受体阳性4级侵袭性乳腺癌的患者,正在考虑AI治疗,可以接受初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "6e4be816-3da7-4def-ab23-2a4fda805cd0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "激光辅助荧光血管造影和后部放射性切口均用于初级试验中。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "90cecb95-9f89-4747-81c3-96545edaf3f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "在初级试验中,没有两个病人出现同样的不良反应。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "137bb76f-a37e-4339-af7e-f0c647a01baa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "初级试验的Bevacizumab组比Bevacizumab+Capicitabine组发病率或死亡率高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c41ed5cf-4629-4a4f-b564-197d705ec9cc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "初级试验和二次试验中没有不良反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "956a23c9-f76f-4492-9f00-acdbaf6ac083": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "在初级试验中所记录的大多数不良事件是与血液和骨髓有关的,但二级试验并非如此。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b87ab44e-6cbe-4567-98ff-bd820aa7edeb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "有13 % 的 HER2 初级乳腺癌患者接受 HER2 靶向 PET/CT 治疗 89Zr-trastuzumab 发展出可观察的 HER2+ 转移",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e2e8bb00-df98-49c2-a81b-e18ae21516aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "初级试验的安慰剂介入和合并MSC介入均用相同的剂量注射一次心肌间注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6b3619d3-21ea-437e-bb0f-f124cf636ca5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "初级试验的参与者在1、8、15日接受 HER2/neu肽疫苗,并加入沙拉莫斯汀(GM-CSF)ID",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "0c03c804-4144-4d84-b740-8f6040f15acc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "一位20岁的女性患者患上了新诊断的急诊阳性, HER2阳性乳腺癌,可接受二级和初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c08aa0d8-5505-438c-b53a-934bd2ee570d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "LBH589和Lapatinib组的初级试验没有报告任何结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "0a1cb41e-a5f8-42ca-bec7-f9bc1291037c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "初级试验第1号干预中所用盐酸的剂量比二级试验第1号干预中所用丹索马布的剂量高12倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ddf4fc68-7920-4212-ac8b-7453ebeb49fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "两组初级研究组将接受相同的18F-FDG和18F-FPPRGD2正电子发射成像/计算机成像(PET/CT)成像程序。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "09879638-e324-4f5d-a45e-f62f7e06f301": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "儿童和青少年没有资格参加初级试验,因为他们不符合身高要求,但他们没有被明确排除在二级试验之外",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "bc50160f-7490-4c30-b373-9474707b02b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "初级试验中没有出现任何不良反应,二级试验中没有出现任何不良反应,除皮肤感染外,有超过30%的病人受到影响",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "ee2fe2ab-dc6f-434e-b0dd-1deee5fb3d31": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "参与者必须对AI治疗有抵抗力,才能参加初级试验,但这并不需要被纳入二级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "7d818afc-93da-4098-a0f0-558bc0095687": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "18岁以上的女性癌症患者可以参加初级试验,无论种族、种族来源或癌症类型如何,但对于第二期试验,她们必须有BRCA+乳腺癌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e04edb9d-dc0e-44c4-abb9-3260b400e265": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "二次试验和初级试验都使用了用CogState测量的客观认知功能分数作为测量单位。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "初级试验的第二组参与者比第一组参与者多7人",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            21
        ]
    },
    "e63ac45b-c34b-4007-820a-30202893fc6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "初级试验中只有有限的数量的病人被诊断出具有克拉斯或BRAF突变的转移性大肠癌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "ff11f88f-a4cb-481e-bf56-afa5c0adda19": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "次性试验在其患者群中记录的不良反应总数比初性试验略多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "29bed237-ccbb-460b-a50b-fbdc9e52fdd1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "初级试验中所有 AE 类型均影响不到10%的病人",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "88951a9e-179e-4284-9f98-141eb3d76369": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "Aes 未被记录在初级试验或次级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "71698d59-3bbe-4e8f-85c8-bf2110727155": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "初级试验中只有4种不同类型的不良反应影响了2组患者",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "970f06b2-0935-4cde-a070-ddd7adb8ed5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "性别并不是初级试验资格的决定因素,但只有女性患者才能参加二级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d0168033-35eb-4032-b6e5-f81d9d3a9f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "在初级试验中,未接受 topical cryotherapy的病人的症状比接受 topical cryotherapy的病人要差。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cf4c4c98-b8b0-4ab8-85a8-1269da4d9fd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "在二级试验和初级试验之间没有共享的包含/排斥标准。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3d100b36-5765-4953-b072-b06f38b6958c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "初级试验的帕克利泰克勒+贝瓦西祖马布+杰姆西达宾组比帕克利泰克勒+贝瓦西祖马布组有更好的ORR",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f0ca21dc-bf98-4c8b-b08e-d0821905846a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "针灸患者在初级试验中发现他们的淋巴结肿比在候诊名单上的病人有更好的改变。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "b88356ec-038f-4f5c-bf14-750059dbba4f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "初级和次级患者群组中最常见的不良反应是辛柯普",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "56e9308b-f718-4831-8e56-4b18982e4a2c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "病人的国籍、种族、体重或性别不会影响其接受初级试验或次级试验的资格",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "86ee12d2-2095-4ece-a7d6-f9494b51f3a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "第一项试验是使用激素干预,第二项试验是检查针灸干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8ef6757e-e789-4a70-9cf3-e2e8050c9f15": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "初级试验和次级试验在其结果中评估了不同病人的特征。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "52d4cfdf-7677-4f4c-8020-4f5271393df9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "参与初级试验的病人每天两次接受口服药物,为期一个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "a8932849-e870-422e-a81a-1b43d9622082": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "基托罗拉克30 mg组初级试验的生存率与NaCl0.9%3mL组相比为-6.4%无复发",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "06a1adac-dee0-4d9b-83c6-0996391e40d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "主要试验13名参与者接受Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH共用疫苗",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c2d6b8ba-8238-49b7-b9a1-de2ffdabe324": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "目前参加二级试验的病人也符合资格参加初级试验,因为他们具有相同的入息标准",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "496667f2-e493-4b4e-a257-7b8de3833e8b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "在初级试验中,安慰剂和Trabectedin的介入方式相同,但不同日期。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "47512f16-9809-4150-a101-1fb7256c5bf3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "二级试验用肌肉增益作为物理治疗效果的指标,而初级试验研究硫磺酸补充剂对尿中的异氰酸盐浓度的影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d904b234-fed6-473e-bd40-8f37f4a4e440": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "初级试验和二级试验并没有测试相同的药物",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "90c519e9-7981-4a72-af6a-cc032657458a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "初级试验干预部分需要外科和影像处理。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d9e7c0cc-0850-4a8e-b389-092dfdc623fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "有组织记录的转移性SCBC的病人被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "05fbffcf-c1a0-40f9-95dd-8e9010005773": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "二级试验和初级试验报告来自一组患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "7814620b-23de-463b-8fd1-efdf51ce26b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "在过去3年内,有ILD/DPLD诊断的成年人,预期寿命为6个月,可接受初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            19,
            22
        ]
    },
    "ae548af6-b401-4dac-9824-50b2a566e7bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "18 岁 的 人 被 排除 在 次级 试验 之外, 但 初级 试验 没有 规定 参加 的 年龄 范围 。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "a60074c0-d7a6-47cc-b980-ee1c0a791f66": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "初级试验的两组组接受了同样的阿布拉克森剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d9d506ef-20ed-44e2-9809-07cb0772535b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "初级试验中所有感染和感染病例均为1组患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1defe036-8290-4a01-bec7-f75305d1e88e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "无论是二次试验还是初级试验都用厘米、参与者数目或时间单位作为衡量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "1fe68175-6ac4-4439-818f-94758e6bd306": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "在初级试验中,未接受帕克利塔克勒灌注的病人的症状比接受帕克利塔克勒灌注的病人要差。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "fac10570-e1ed-4b0a-b847-55eb25265d25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "在第一组初级试验中记录了1例贫血和 Febrile neutropenia,但没有 Pancytopenia 的病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "152fc619-bbb0-40ff-aa3e-5722f62f6a84": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "第一组和第二组的患者接受相同的放射治疗量,但第一组的介入持续了两个星期。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "228308ea-2483-4311-a975-ca974ff797c6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "参加初级试验的人没有患上UTI",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "eca5c391-f479-448d-bff8-313a7df673b4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "初级试验和次级试验分别对患者群进行环磷酰胺、帕克利塔克塞尔和佩格菲尔格拉斯汀的投与",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "17660aaf-9218-4119-b00c-f3b863718e97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "第一组接受了与第二组相同的Cetuximab剂量,但有额外的协作护理干预",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "291150cd-0d45-46c7-9a44-d781098bc3eb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "超过18岁的女性癌症患者可以参加初级试验,无论种族、种族来源或癌症类型如何,但对于次级试验,她们必须有Her2/neu+乳腺癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "403ad287-6e25-4db0-a66b-fe4a7f15a983": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "一个具有33毫米直径的初级肿瘤,经临床检查和扫描仪测定,可以接受初级试验和二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c389c3cc-2e76-4219-996d-3aa5a925fec7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "二级试验和初级试验在其结果中使用不同的测量单位,用于相同的结果测量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            9
        ]
    },
    "6f0571f4-e1da-4732-9bdf-8c07bea059c1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "二级试验和初级试验都用同样的测量单位报告结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "c6ca9f93-1abb-4c01-bdfb-aa17c5028ec8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "一位年轻的女孩患上了新诊断的艾滋病阳性, HER2阳性乳腺癌,可接受二级试验和初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b16d4167-cb81-44c0-b20d-d1ecbf0bc094": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "初级试验的介入是局部的,而二次试验的介入是通过插入静脉的针或管进行的",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "36cbd8dd-9c77-496c-ab43-af1942c86339": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "初级试验的两组组接受了阿布拉克森和卡博普拉丁相同的剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "50dae016-a6b4-4ee6-a66a-bf35587cd835": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "初级试验的患者平均存活超过2年,但至少有两名患者在2年以下死亡。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c63468c0-324f-4528-b83f-a588ccf7b680": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "直径100毫米的TNBC肿瘤的病人,可接受初级试验和次级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ]
    },
    "ef2af81d-e19c-49c9-8ff0-309b87eb6f38": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "初级试验只记录了其患者群体的单个不良事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4714a31c-c7ca-49e2-aa71-6665b65ed04f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "病态肥胖的病人可以接受初级试验和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "570b88e9-5036-4ea8-80db-0f48696700af": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "所有初级试验参与者接受的ALT-801剂量高于次级试验参与者",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f7de4d97-31e4-48e0-ab1a-1e3d8a152e8b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "在二级和初级试验中,大多数病人没有发生任何不良反应",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8d685159-80a2-4b2c-8ca3-066d03e1cf66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "口服黏膜炎、癫痫发作和血栓栓塞发作的病例较二级试验多",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "5e93b7d7-89d9-47cd-98b4-5897823889fa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "初级试验组1组注射氟酰胺,次级试验组1组标准剂量氯基安。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "2e42ac97-e353-4bbc-b61e-391e0c092689": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "初级试验的介入1和2的唯一区别是,1组与2组相比,每星期两次注射的Durva剂量减少0.7mg/kg。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0585f6bd-d582-4fc9-b96b-1355fa083e33": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "初级试用者需经皮下注射7种不同的药物并接受手术治疗,而次级试用者只接受2种不同的药物和数种不同的影像扫描",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4f1bafd9-361f-4981-b6fd-46af736141b4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "初级试验干预部分没有概述治疗周期或照射剂量的描述。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "初级试验的患者平均存活超过2年,每组超过50名患者存活超过24个月",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0bb34f7b-d21a-4057-876a-25c722e6d50e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "在初级试验中,97%的病人没有发生任何不良反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "3f15d923-bf66-4188-8714-c9ae4921de1f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "二级试验和初级试验至少有一项包含标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9562c377-c748-46d7-a5f2-eb492d20e477": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "初级试验两组中,有0例高血压、脱水和呼吸困难",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "1e24905e-7bf9-4a79-8157-8948f108ecb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "初级试验组的尼特接受任何侵袭性手术或尼拉提尼布",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "57656a6d-8e1c-4cb8-b80d-605174d0577c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "任何患有纤维性肌痛、溶血症候群或贫血的癌症病人都不能接受初级试验和次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "c5ece9f7-9119-4fa2-b60d-f2f15c68ae02": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "复发性恶性肿瘤、移植与宿主病、贫血、心脏衰竭和扩散性肺出血在初级试验的不良反应中均较次级试验更为常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "8f8be6b6-df75-4757-bc64-b2fbc8849f70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "第二次 审判 第二组 记录 有 一 宗 尖峰 案件, 但 第二组 和 初级 审判 第1组 未 记录 任何 案件 。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "520f44e8-b74b-44a6-a7cf-496275847af1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "初级试验的两组都记录了0Aes",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0c902de2-30b5-4ab8-9739-70be987d043a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "初级试验中的2组2名患者中,25%患上胸腔扩散症",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            7
        ]
    },
    "8b98421d-1cec-41bd-b25e-2e73c362193a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "病人的国籍、种族、精神状况或性别不会影响其接受初级或次级试验的资格",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12
        ],
        "Secondary_evidence_index": [
            34
        ]
    },
    "62441471-f329-4540-9d4e-dc34c4d08d59": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "第二期审判的候选人必须完全不能参加,而这并不需要被接受第一期审判",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "在第一组与第二组相比,有4名患者患上不良反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "cf45d975-0c29-4cf3-8f21-c245482a2b32": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "二次试验和初级试验完全没有相关的结果测量,但相同的干预",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fb011e19-d4fb-4e6c-b7c9-7a7238f78970": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "无论是二次试验还是初级试验,都无法测定他们研究中体验临床疗效的参与者百分比(使用(RECIST)标准)",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "fd800c89-d30c-4a9a-970b-5385deeab52f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "次级试验的2组患者比初级试验的2组患者多得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            17,
            18,
            19,
            20
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            7,
            16
        ]
    },
    "d0212d75-c952-4ad3-ae36-bbf675eae985": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "主要试验组2的50%以上患者在用阿普里平特、德克萨米沙酮、赛托克森和基特里尔治疗后急性呕吐",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "5d98b3df-684a-466d-93da-5a672f602db6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "初级试验的参与者接受佩布罗利苏马布的频率比次级试验的参与者接受桑尼丁比的频率要高两倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "61a6a476-9283-4cde-89e7-5f1405f690c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "参与初级试验的病人每天两次接受100 mg/m2口服拉帕提尼布,为期一个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "bde8a5a0-02fc-4b6e-a91a-a56c420d9c3b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "初级试验和二级试验评估有初级利益不良事件的参与者百分比",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fabf3f7a-48df-4940-93e2-8cbe976c4246": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "初级试验两组中,有0例高血压、风湿和呼吸困难",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "e8351b8b-d707-4766-b875-777557f0653f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "腹膜灌注在初级试验中比较常见,而角膜沉积在次级试验中比较常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "5dea6bbb-13c3-470c-98a6-3879f17de8c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "初级试验报告了研究中所分析的参与者总人数,但没有报告每个群体的参与者人数。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            21
        ]
    },
    "5c00eee7-bb33-45e5-97c6-4cfc34946cdf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "初级试验没有测试药物治疗,而次级试验测试一种药物治疗的不同剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c3f4b547-8d11-42ba-800c-7ccbe1283741": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "乳腺癌患者以雌激素负、孕酮负和HER2肿瘤为准接受所有组别的初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "451c8e9e-03c1-4b7a-9b84-5129c5623f1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "初级试验的候选者必须患乳腺癌,并需要激素治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2
        ]
    },
    "7723c9e5-e80e-4ef6-b56d-ee26f8423d90": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "初级试验结果报告了延迟性吐痰的严重程度,次级试验测定了腰椎骨矿物密度(BMD)从基线变化到9个月",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b6b719ca-e7f3-4254-a1a0-2946acbcd2fd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "初级试验的AZD0530 175 mg组的初级肿瘤直径比 Zoledronic Acid 4 mg组要小。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b3f59657-9278-41be-b740-433b0d38fdd5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "有TX NX MX、T0 NX M0或T1 N1 M1肿瘤的病人可接受初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "bcc9a793-5002-4cd9-a5b7-af5a1ceca35a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "初级试验的候选者必须患结肠癌,并不能对先前的激素治疗作出反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2
        ]
    },
    "3a141563-97b8-4154-8c9c-f1f551ec7969": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "初级试验的两个组别都未获得阿利塞提布,而次级试验的两个组别则获得不同的剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "64441aad-b959-41bb-aa81-2f594d00b70c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "候选者必须在参加初级试验前进行乳房扫描,而次级试验患者必须先进行CT扫描和血液测试。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "5fcf6210-c07a-4b8e-9944-c2f0714e4d69": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "所有初级试验参与者接受的药物剂量比次级试验参与者要低",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "05530068-7a95-46f6-88d2-84e53ee2ff35": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "一般症状是初级试验中最常见的 AE",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "40fc3a97-0a5d-4f19-ba94-7c4668d0538d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "阿里米德克斯在初级试验中的两组中都使用,但在二级试验中完全没有使用",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f0f8a0a6-1148-4592-a9b4-27c005038900": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "初级试验的参与者在整个研究期间接受了4种不同的药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2cde3c46-f21a-4177-afc8-94f851854b98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "初步试验中至少有1例胃肠道不良反应",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "b3679900-ab99-4a84-83e0-fc1122a43beb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "所有在研究进入前一个月接受抗肿瘤化疗、安德rogen 、 Estrogen 或 Progestogens 治疗的病人均被排除在初级试验之外。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "21afdaec-2db5-42b3-b201-b2dee4e23cb7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "初级试验和次级试验在他们的介入中并没有使用相同的药物、剂量或投药频率,但他们都使用静脉注射和MRI。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b9b69888-f771-4a3a-b6f0-825510997cca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "首次试验的1组患者在2组患者中接受的ALT-801剂量少于一半",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6d7c7740-c399-4d73-82c8-2ef0d4739341": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "初级试验的第1组没有报告Aes",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "15577bb6-3b4d-4373-ae58-eb0bf0c34954": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "对初级审判的候选者,禁止使用碱治疗,但他们仍可参加二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            31
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "315f4573-d5b1-4cbc-9efb-74c27a98dc6d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "被組織學證實的第4期乳腺腺癌(英语:Stadium 4 breast adenocarcinoma)是 ER陽性、PR陽性或HER2/neu陰性患者,可以接受二次和初級試驗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4
        ]
    },
    "fe6baecc-71eb-4b15-ba15-66d57539c702": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "同样的百分比患者在两组初级试验中都遭受了不良反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "在初级试验中,最长的PSF患者生存了3.5个月,没有疾病进展或死亡",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f9e4988c-a325-40bc-8220-e7d0c404fd37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "在初级试验中所记录的单个不良事件类型中,没有一种影响超过四分之一的患者群体",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ef2352dc-a976-47c6-91cd-6666e3f7b55a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "初级试验是评估治疗相关不良事件的病人人数,而次级试验则以小时计量病人平均睡眠时间。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "初级试验1组患者的不良反应比2组患者多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "9cd25233-1d76-4d0d-a571-ce8fee279757": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "患有肥胖症和怀孕的病人可以参加初级试验和次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "0c27bcc9-3108-4d4a-901a-22718c22d288": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "大多数初级试验的病人在24周前都得到了完全的反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "464e2cd9-6c59-4692-a3fc-083c374f4a5c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "初级试验中的两种介入包括相同的帕拉普坦剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "438a978d-ac7e-4260-bb24-d2129cb3dfc6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "严重失眠和精神分裂症患者不参加初级试验和次级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            6
        ]
    },
    "863f7074-fb4b-4c82-9e30-bb785f85f816": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "初级试验和二级试验的介入都要求病人每周接受4-Demethyl-4-cholestryloxycarbonylpenclomedine",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "eeb18145-fc5f-41d7-bce3-245d21000e7b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "接受1000 mg + Nab-Paclitaxel治疗的初级试验中,超过1/2名患者有证实的完全反应(CR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ad5ca7e8-3e5d-43b8-9618-99f56fc70290": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "在初级试验和次级试验中,没有记录心脏或精神病性Aes,但观察到其他类型的Aes。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3eb3c09a-b46f-49bf-84d6-7aeb1ba0d2a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "主要的試驗介入包括使用Yttrium-90玻璃微球和TheraSpheres的放射栓塞,另一方面的二次試驗介入包括560 mg的ibrutinib和10 mg/kg的 MEDI4736每天两次一个月。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7dd6b446-5585-4660-8bc7-e9811af66268": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "目前吸烟的病人不能参加初级试验或次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "f45bbf0b-4acd-4166-81a6-6b407cff87ca": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "初级试验测试不同凝胶对研究组的影响,而次级试验测试不同剂量相同的治疗对研究组的影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b23563cf-e6c4-4279-92b7-39d5e4de96d2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "初级试验或二级试验的组别均未接受肠内膜片",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d921df56-8a29-45a9-bb0b-66ba14dbc193": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "所有在研究进入前2年接受抗肿瘤化疗、安德rogen 、 Estrogen 或 Progestogens 治疗的病人均被排除在初级试验之外。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "006c9dd6-c568-4497-81b7-c954568a3b4a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "乳腺癌患者接受1000毫克/日塔拉佐帕里布,而卵巢癌/腹膜癌患者接受25毫克/日塔拉佐帕里布。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "585b42d5-c81a-482a-a6bf-b7db6c6edcfb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "初级试验第1组中只有61名颈癌患者在介入前进行筛查。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "620b6390-df07-45fe-9ef9-55a32521c740": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "初级试验组的腹泻比次级试验组的腹泻更为常见",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ],
        "Secondary_evidence_index": [
            6,
            21
        ]
    },
    "eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "初级试验1组的100.0%患上某种不良反应",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "9334239a-f4f1-4192-a35d-93c25c41328d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "初级试验的particpants接受Epacadostat的频率是Sunitinib-na参与者接受 sunitinib的频率的两倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "feca7444-9108-45e9-b722-4f0a207376c7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "缺乏维他命D的病人被排除在初级试验之外,但可能有资格参加次级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "2e2a005f-232f-457a-880e-c3950bc58df6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "初级试验和次级试验的介入包括完全不同的基于药物的治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "b95564b8-cdbe-45d0-be91-764d6768e5f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "初级试用者每周接受的MM-121和帕克利塔克塞尔剂量少于第二级试用者1组,但用量较高",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2ce0822a-fcf8-4010-950c-0d3a8dc2cb00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "任何对头孢子素、三甲普林/硫法甲基沙唑、 levofloxacin 或 selecoxib 有记录过敏的病人,均不能参加二级和初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            24
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "e6bba244-c154-4143-a5f2-5f8b1c304a97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "怀疑严重不良反应在初级试验的不良反应部分比次级试验更为常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a5657dcd-1ee5-44f6-bb21-e718259c4b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "初级试验第2组没有死亡或住院,只有一例心房颤抖。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8180d5e0-b284-45fe-a390-0c3a54dc663f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "初级试验组1例注射注射氟沙拉丁,次级试验组1例注射氯基安的标准剂量为IV。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "87fda661-4348-4078-b3e7-915893241ab0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "苏拉明和帕克利塔克塞尔在初级试验和次级试验中被投给所有病人",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4bc60955-6137-4496-b780-5fb8e90dc3ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "胶囊性淋巴疹是主要试验参与者常见的不良反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7ad6c209-8893-4a2d-963d-24666ef93a80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "两组初级研究组将接受相同的18F-FDG和18F-FPPRGD2正电子发射成像/计算机成像(PET/CT)成像程序,但1组会接受略高于18F-FPPRGD2的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a06166e6-12c9-49ba-ad3a-7fcfb5234174": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "二次试验和初级试验的结果是完全无关的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "73feb437-66f3-44fd-8d9c-ab3204e6eac3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "在初级试验中,在1组病人身上出现了几个记录的Aes",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "927d72b0-1f55-4803-9a86-40838c08f923": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "初级试验要求病人每月注射120毫克丁诺沙马布,次级试验也需要注射0.4至1.0米西的放射性Tc99M硫胶。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "19e0531d-7907-46b0-ab0c-e616746498e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "第2组接受0.5ug/kg的Dexmedetomidine(5ml),第二组患者不接受任何Dexmedetomidine。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fc281ab7-f956-47d7-a938-8778fef1bca0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "第二期研究组的候选者每周接受3次皮下注射(SC),而初级研究组的参与者在研究开始时只接受一次注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6261a694-0407-4840-8a87-3a0c6f9dea4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "初级试验每隔2周和6周对1组病人进行150毫克的口服前加巴林治疗,次级试验对Depocyt和HD-MTX患者进行治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9730b1a6-e9cd-4fd6-b1e4-9916b5903c63": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "总共有2名初级试验患者,每组有1名患者患上剂量限制毒性发病率。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "2fb3af20-adda-4fee-860a-ce376d3a0bb2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "初级试验结果显示,12周较24周有较多的稳定病例,但12周或24周有0例完全反应的病人",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "f8dbd18d-2b55-4f0f-92a7-db3b1ecc3b6d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "初级试验和次级试验在患者群中记录了相同的不良反应总数。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "dd27a6e7-3b83-4a84-bc40-5ba39617a1c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "那些有组织记录的转移或不可切除的SCBC的病人,除非在急诊或急诊或两类反应中获得阳性,否则不会参加初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "113abff0-a728-40a6-b637-8bd60a53e626": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "第一组接受了与第二组相同的Cetuximab剂量,但8mg/kg MM-121少于第二组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1cb125fb-0be1-49c6-b68b-64b525278c9c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "在一次性试验和二次性试验中,在不良反应中只记录了一次死亡。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fd0b22b0-c86d-4460-bf53-310901404ef5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "所有初级试验候选者必须有HER2阳性肿瘤,并经FISH阳性或IHC3+阳性证实",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "c0151b24-14ab-4837-965d-88bb8115a560": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "初级试验中,最长的PSF患者是1组,他生存了3.5个月,没有病态发展或死亡",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "1d66459b-4624-4ea0-9cda-992c4146a454": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "使用加巴彭汀或前加巴林的预先治疗将导致被排除在二次试验中,但不会被排除在初级试验中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            12,
            13
        ]
    },
    "73981f59-887e-4778-a78a-0bf7b7a405b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "初级试验记录的不良反应比次级试验记录的不良反应多4次",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "dbd5f70e-0fa9-4b5e-af0e-0ad9efc49bc6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "没有X射线、超声、CT扫描或MRI包括初级试验和次级试验的介入",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5599d5d8-3a7b-41ce-a00c-6e0b609b618d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "初级试验1组的100%患上至少1个生命危险的不良反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "84942825-f636-4dcf-af2e-172012c0cc9d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "初级试验1组患者接受的Cyclophosphamide剂量高于Eribulin,2组患者接受的Cyclophosphamide剂量高于Docetaxel",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e4b448ba-15ad-4cf8-9343-782d45166891": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "初级试验和次级试验研究同一药物,不同剂量,不同结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "27aec260-8dcc-4611-8389-dc9c10d3518d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "初步试验结果表明,在手术前7天和乳腺癌手术后14天内,每天32毫克的塔莫西芬可平均减少肿瘤的直径40%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "943f62ca-d87c-4a5e-9355-6750d7d9b58f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "初级试验的介入1剂量比二级试验的介入1剂量高12倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e53898b8-422f-4317-b2f6-c487409b0750": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "总的来说,初级试验中贫血病例较次级试验少.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            17
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "7b819ac1-92e6-41ce-881c-0f4581a690ee": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "在初级审判中,感染、不对称和衰减的病例比次级审判多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c09c08d5-189f-4e15-acb8-2c3cb235aaa6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "在初级试验中,两组患者均报告了同样数量的Aes",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "99a6cb19-b6d8-4cb7-84e1-be559854caa6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "所有初级试验的病人每3周至少接受20mg的MCS110。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "70539b18-50b0-43f7-b676-2143de2dc3e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "初级试验和二级试验都对患者群进行环磷酰胺的投与",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "52b055fd-9e0d-41ad-9eb7-1a724cbc0112": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "与初级试验组相比,结果没有显著差异,但在第二期试验中,反射组和控制组的结果中发现了一些差异。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "dcfc0053-b963-4542-ae02-228d3d2bd98e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "初级试验中的介入包括不同的药物,但采用相同的方法。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f706897d-d54e-4449-8bc7-da0bd6fbad01": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "经考评分1的考生可参加初级及二级考试",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "c39ec45a-1664-49aa-8356-abbecf045001": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "在二级和初级试验中,超过97 %的病人没有发生任何不良反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "eb555e01-0a12-45a1-99ad-7d7dafbe8912": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "初级试验A组和B组在同一周期中注射相同的两针LDV935。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c43583e4-da5f-42b3-ad3d-7ba8b6b28f2b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "次审记录了11例肠道穿孔病例,比初审记录了11例肠道穿孔病例",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "094e7aec-88db-4ad0-b995-ece8587fd48b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "没有X射线、输血管注射、CT扫描或MRI,包括初级试验和次级试验的介入",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "20c98ba5-ca61-4afe-af57-6de08705a5cd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "二级试验和初级试验采用不同的结果测量和测量单元。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "58fa0ef4-0355-42bc-8378-fef98752b05e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "初级试验的病人在整个研究期间都将获得高剂量α脂酸,最多每天三次服用100毫克,而次级试验的第1组患者则在整个研究期间都接受相同的剂量尼基穆马布。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b033d45a-c039-42de-a073-3c051c6f1e3c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "超过1/2名接受1000 mg + Nab-Paclitaxel治疗的初级试验患者经历了确认的完全反应(CR)或确认的部分反应(PR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "75c55f70-aa52-4794-aae7-3a355f1a76e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "乳腺癌患者具有雌激素负、孕酮负和HER2肿瘤的资格接受初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "070ba2da-932a-4a62-861e-3f2c89630b4d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "大多数初级试验候选人在研究期间都患了某种饮食紊乱",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7
        ]
    },
    "76d498ce-037c-4f7e-8cbb-450d8f6019ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "任何性别的病人都可以获得初级试验的两个阶段的资格,如果他们有证据显示有固体肿瘤,其局部进展和/或转移。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "dfd8e736-5ef2-4d36-b124-9382e72f982d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "速呼吸干预组的初级试验病人平均每天的热闪光少于速浅呼吸组的病人。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "a4a2c0ba-3fa9-4fad-9258-7e517ae85e25": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "酒精中毒患者不参加初级试验,但如果他们每天饮用少于5杯酒精饮料,则可以参加次级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e8e3fedb-075d-440e-bf2e-baec76f96cca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "经组织学/细胞学证实的非小细胞肺癌或小细胞肺癌的病人,可接受初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10
        ]
    },
    "b53a2698-dfb0-416d-9f3e-2e800a360b3e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "初级试验用150毫克口服前加巴林治疗1组患者,次级试验用Depocyt和HD-MTX治疗1组患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "cd067ee2-ed1d-403b-aa50-d61a3399fda3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "基67表达的细胞百分比在1个月内在初级试验中出现10%的降低。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "8b50bdc1-1722-403b-a854-adeaacd02acb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "患有急性厌恶性反应的病人,或对赫塞汀治疗药物的无反应的病人,可以接受初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17
        ]
    }
}